{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"}]}],"title":"MCyR within first 12 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"}]}],"title":"MCyR within first 24 weeks"}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Cytogenetic responses were based on the karyotype analysis of the percentage of Ph+ metaphases among cells in metaphase on a BM sample. At least 20 metaphase cells from a BM sample were evaluated. MCyR: A cytogenetic response that was either CCyR or PCyR. CCyR: 0% Ph+ cells in metaphase in BM. PCyR: \\>0% to 35% Ph+ cells in metaphase in BM.","groups":[{"description":"Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP). Dasatinib 60 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG000","title":"Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2)"},{"description":"Participants with imatinib-resistant Ph+ chronic myeloid leukemia (CML) in chronic phase (CP). Dasatinib 80 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG001","title":"Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2)"}],"paramType":"NUMBER","populationDescription":"All treated participants in stratum 1: Participants who received at least 1 dose of study therapy.","reportingStatus":"POSTED","timeFrame":"After completion of Week 12 and 24 (measured at Weeks 13 and 25)","title":"Number of Participants With Major Cytogenetic Response (MCyR) in Stratum 1 (Ph+ CP-CML) Within First 12 and 24 Weeks","type":"SECONDARY","unitOfMeasure":"participants"}